Results from a phase 1 open-label dose escalation and expansion trial of oral Azacitidine + Cedazuridine (ASTX030) in patients with Myelodysplastic Syndromes (MDS) and MDS/Myeloproliferative Neoplasms (MPN) 

Phase I/II study of the all-oral combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML

Oral Decitabine/Cedazuridine in patients with MDS and TP53 Mutations: A propensity score matching analysis from the phase II and III trials 

Real-world use patterns and clinical outcomes for Myelodysplastic Syndrome patients initiating oral Decitabine and Cedazuridine or intravenous/subcutaneous hypomethylating agents

Personalized oral maintenance therapy with Decitabine/Cedazuridine (ASTX727) combined with a molecularly targeted agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in acute Myeloid Leukemia in first remission

Fully oral combination of Decitabine/Cedazuridine (ASTX727) plus Venetoclax for the treatment of newly diagnosed acute Myeloid Leukemia in patients ineligible for intensive chemotherapy